Aspira Women's Health: Director Departs, New Director Appointed
Ticker: AWHL · Form: 8-K · Filed: Sep 3, 2025 · CIK: 926617
Sentiment: neutral
Topics: board-change, management
TL;DR
Aspira Women's Health board shake-up: Gelfond out, Smith in.
AI Summary
Aspira Women's Health Inc. announced on September 2, 2025, the departure of Director Dr. Jonathan M. Gelfond and the appointment of Dr. David L. Smith as a new director. The company also reported on compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine board and officer changes, with no immediate financial distress or significant operational shifts indicated.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Dr. Jonathan M. Gelfond (person) — Departing Director
- Dr. David L. Smith (person) — Appointed Director
- September 2, 2025 (date) — Date of earliest event reported
FAQ
Who is Dr. David L. Smith and what is his background?
The filing does not provide specific details about Dr. David L. Smith's background or qualifications beyond his appointment as a director.
What were the reasons for Dr. Jonathan M. Gelfond's departure?
The filing states Dr. Jonathan M. Gelfond's departure but does not specify the reasons for his exit.
Are there any new compensatory arrangements for officers detailed in this filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not provided in the excerpt.
What is the significance of the 'Election of Directors' item?
This item indicates that the company has elected new directors to its board, which is a governance-related event.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K occurred on September 2, 2025.
Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-09-03 17:22:30
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWHL The OTC QB Market
- $300,000 — erford will receive an annual salary of $300,000, payable semi-monthly, and he will be e
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 119KB
- ex10-2.htm (EX-10.2) — 30KB
- ex10-1_001.jpg (GRAPHIC) — 85KB
- 0001641172-25-026441.txt ( ) — 501KB
- awhl-20250902.xsd (EX-101.SCH) — 3KB
- awhl-20250902_lab.xml (EX-101.LAB) — 33KB
- awhl-20250902_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: September 3, 2025 By: /s/ Michael Buhle Michael Buhle Chief Executive Officer